{"id":"rasburicase-sr29142","safety":{"commonSideEffects":[{"rate":null,"effect":"Allergic reactions (including anaphylaxis)"},{"rate":null,"effect":"Hemolysis (particularly in G6PD-deficient patients)"},{"rate":null,"effect":"Methemoglobinemia"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Nausea and vomiting"}]},"_chembl":{"chemblId":"CHEMBL1201594","moleculeType":"Enzyme"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Rasburicase breaks down uric acid into allantoin, which is approximately 5–10 times more soluble than uric acid in urine. This prevents uric acid crystal formation and reduces serum uric acid levels rapidly, thereby preventing or treating tumor lysis syndrome and associated complications such as acute kidney injury and hyperuricemia.","oneSentence":"Rasburicase is a recombinant urate oxidase enzyme that catalyzes the conversion of uric acid to allantoin, a more soluble metabolite that is readily excreted.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:04:00.240Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Tumor lysis syndrome prevention and treatment in patients with hematologic malignancies at high risk of rapid cell turnover"},{"name":"Hyperuricemia management in patients receiving chemotherapy"}]},"trialDetails":[{"nctId":"NCT07116746","phase":"PHASE2","title":"Evaluation of Efficacy and Safety of AR882 and XOI Co-administration in Uricase Treatment Failed Patients","status":"RECRUITING","sponsor":"Arthrosi Therapeutics","startDate":"2025-12-03","conditions":"Gout, Gouty Arthritis, Hyperuricemia","enrollment":25},{"nctId":"NCT04745910","phase":"PHASE4","title":"Pegloticase for the Reduction of Uric Acid in Patients With Tumor Lysis Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2022-04-05","conditions":"Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Tumor Lysis Syndrome","enrollment":10},{"nctId":"NCT01046825","phase":"PHASE2, PHASE3","title":"Mature B-Cell Lymphoma And Leukemia Study III","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2010-09-09","conditions":"Mature B-Cell Lymphoma","enrollment":128},{"nctId":"NCT04987294","phase":"PHASE2","title":"Phase IIa Study of ALLN-346 (Engineered Urate Oxidase) in Subjects With Hyperuricemia, Gout and Chronic Kidney Disease","status":"TERMINATED","sponsor":"Allena Pharmaceuticals","startDate":"2022-09-02","conditions":"Hyperuricemia, Gout, Chronic Kidney Diseases","enrollment":19},{"nctId":"NCT04987242","phase":"PHASE2","title":"An Inpatient Study of ALLN-346 (Engineered Urate Oxidase) in Hyperuricemic Subjects (Study 201)","status":"COMPLETED","sponsor":"Allena Pharmaceuticals","startDate":"2021-07-16","conditions":"Hyperuricemia, Gout, Chronic Kidney Diseases","enrollment":16},{"nctId":"NCT05312268","phase":"PHASE4","title":"Rasburicase Treatment in Chronic Gouty Arthritis","status":"UNKNOWN","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2022-06-15","conditions":"Chronic Gout","enrollment":60},{"nctId":"NCT00199043","phase":"PHASE3","title":"Treatment of Hyperuricemia With Rasburicase in Patients With Acute Lymphoblastic Leukemia or High Grade Lymphoma","status":"COMPLETED","sponsor":"Goethe University","startDate":"2003-05","conditions":"Adult Acute Lymphocytic Leukemia, High-grade Lymphoma","enrollment":80},{"nctId":"NCT05168683","phase":"PHASE1","title":"Scintigraphy Study in Healthy Volunteers to Characterize the Performance of ALLN-346 Tablets","status":"COMPLETED","sponsor":"Allena Pharmaceuticals","startDate":"2022-01-11","conditions":"Hyperuricemia, Gout","enrollment":12},{"nctId":"NCT04349306","phase":"PHASE4","title":"Evaluate the Efficacy and Safety of Rasburicase (Fasturtec®) in the Prevention and Treatment of Hyperuricemia in Pediatric Patients With Non-Hodgkin's Lymphoma and Acute Leukemia","status":"COMPLETED","sponsor":"Sanofi","startDate":"2020-05-14","conditions":"Lymphoma","enrollment":50},{"nctId":"NCT05226013","phase":"PHASE1","title":"Tolerance, Pharmacokinetics / Pharmacodynamics (PK / PD) and Immunogenicity of Pegylated Uric Acid Oxidase for Injection in Healthy Adults and Hyperuricemia Volunteers","status":"UNKNOWN","sponsor":"The Affiliated Hospital of Qingdao University","startDate":"2021-12-08","conditions":"Hyperuricemia","enrollment":54},{"nctId":"NCT04236219","phase":"PHASE1","title":"ALLN-346 Single Ascending Dose (SAD) Study in Healthy Volunteers","status":"COMPLETED","sponsor":"Allena Pharmaceuticals","startDate":"2020-09-02","conditions":"Hyperuricemia","enrollment":24},{"nctId":"NCT04047394","phase":"PHASE1","title":"A Study to Determine the Safety, Tolerability, PK and Preliminary PD of SSS11 in Chinese Healthy Adult Volunteers","status":"UNKNOWN","sponsor":"Shenyang Sunshine Pharmaceutical Co., LTD.","startDate":"2019-10-22","conditions":"Gout","enrollment":33},{"nctId":"NCT04829435","phase":"PHASE1","title":"Study 102: Multiple Ascending Dose Study of ALLN-346 (Engineered Urate Oxidase)","status":"COMPLETED","sponsor":"Allena Pharmaceuticals","startDate":"2021-04-21","conditions":"Hyperuricemia, Gout","enrollment":18},{"nctId":"NCT02297126","phase":"NA","title":"A Prospective Trial to Assess Cost and Clinical Outcomes of a Clinical Pharmacogenomic Program","status":"COMPLETED","sponsor":"Indiana University","startDate":"2015-03","conditions":"Adverse Drug Reaction","enrollment":4465},{"nctId":"NCT03395977","phase":"NA","title":"Uric Acid Effects on Endothelium and Oxydative Stress","status":"COMPLETED","sponsor":"Erasme University Hospital","startDate":"2018-01-03","conditions":"Oxidative Stress, Endothelial Function, Cardiovascular System","enrollment":53},{"nctId":"NCT01200485","phase":"PHASE2","title":"Rasburicase in Patients at High Risk for Tumor Lysis Syndrome (TLS) During Cycle-2","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2011-04","conditions":"Leukemia, Lymphoma","enrollment":55},{"nctId":"NCT01931527","phase":"NA","title":"Effect of Reducing Uric Acid on Insulin Sensitivity and Oxidative Status","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2006-07","conditions":"Obesity, Metabolic Syndrome, Hyperuricemia","enrollment":31},{"nctId":"NCT01323335","phase":"PHASE1","title":"The Relationship Between Uric Acid and Inflammatory Markers","status":"COMPLETED","sponsor":"National Institute on Aging (NIA)","startDate":"2009-03-31","conditions":"Healthy Volunteers","enrollment":97},{"nctId":"NCT01564277","phase":"PHASE2","title":"Rasburicase and Allopurinol in Treating Patients With Hematologic Malignancies","status":"TERMINATED","sponsor":"Roswell Park Cancer Institute","startDate":"2011-09-29","conditions":"Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)","enrollment":24},{"nctId":"NCT00513474","phase":"PHASE1","title":"Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2008-01","conditions":"Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia","enrollment":46},{"nctId":"NCT00186940","phase":"","title":"Rasburicase Treatment for Chemotherapy or Malignancy-Induced Hyperuricemia in Asthma/Allergy Patients","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"2005-03","conditions":"Leukemia, Lymphoma, Tumor Lysis Syndrome","enrollment":16},{"nctId":"NCT00921375","phase":"PHASE3","title":"Safety and Efficacy of TULY (Rasburicase) in Prevention and Treatment of Malignancy-associated Hyperuricemia","status":"COMPLETED","sponsor":"Virchow Group","startDate":"2010-02","conditions":"Hyperuricemia","enrollment":100},{"nctId":"NCT00111657","phase":"PHASE2","title":"Pegylated Recombinant Mammalian Uricase (PEG-uricase) as Treatment for Refractory Gout","status":"COMPLETED","sponsor":"John Sundy","startDate":"2004-12","conditions":"Gout","enrollment":30},{"nctId":"NCT00057811","phase":"PHASE2","title":"Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2004-06","conditions":"Childhood Burkitt Lymphoma, Childhood Diffuse Large Cell Lymphoma, Childhood Immunoblastic Large Cell Lymphoma","enrollment":97},{"nctId":"NCT00607152","phase":"PHASE3","title":"Rasburicase (Fasturtec) Registration Trial","status":"TERMINATED","sponsor":"Sanofi","startDate":"2007-10","conditions":"Hyperuricemia","enrollment":10},{"nctId":"NCT00628628","phase":"PHASE2","title":"Rasburicase in Patients at Risk for Tumor Lysis Syndrome","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2008-01","conditions":"Tumor Lysis Syndrome","enrollment":82},{"nctId":"NCT01097369","phase":"","title":"Elitek (Rasburicase) Immuno-Monitoring Study","status":"TERMINATED","sponsor":"Sanofi","startDate":"2010-02","conditions":"Tumor Lysis Syndrome","enrollment":1},{"nctId":"NCT00756964","phase":"PHASE2","title":"Lowering Serum Uric Acid to Prevent Acute Kidney Injury","status":"COMPLETED","sponsor":"University of Florida","startDate":"2008-10","conditions":"Hyperuricemia","enrollment":26},{"nctId":"NCT00360438","phase":"PHASE1, PHASE2","title":"Pharmacokinetic Evaluation of Rasburicase in Patients With Leukemia and/or Lymphoma at High Risk of TLS","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2006-07","conditions":"Leukemia, Lymphoma, Tumor Lysis Syndrome","enrollment":18},{"nctId":"NCT00664144","phase":"PHASE2","title":"Rasburicase for the Treatment/Prevention of Hyperuricemia in Adult Patients With Relapsing Aggressive Non Hodgkin's Lymphoma","status":"TERMINATED","sponsor":"Sanofi","startDate":"2002-07","conditions":"Hyperuricemia","enrollment":33},{"nctId":"NCT00230178","phase":"PHASE3","title":"Rasburicase Versus Allopurinol in Tumor Patients at Risk for Hyperuricemia and Tumor Lysis Syndrome","status":"COMPLETED","sponsor":"Sanofi","startDate":"2004-04","conditions":"Tumor Lysis Syndrome, Cancer, Hyperuricemia","enrollment":280},{"nctId":"NCT00631579","phase":"PHASE2","title":"Rasburicase as a Uricolytic Therapy for Hyperuricemia in Patients With Leukemia or Lymphoma","status":"COMPLETED","sponsor":"Sanofi","startDate":"2003-04","conditions":"Hyperuricemia, Leukemia, Lymphoma","enrollment":50},{"nctId":"NCT00302653","phase":"PHASE4","title":"Rasburicase in Tumor Lysis Syndrome","status":"COMPLETED","sponsor":"Sanofi","startDate":"2006-02","conditions":"Hyperuricemia","enrollment":33},{"nctId":"NCT00290992","phase":"PHASE2","title":"Rasburicase for Hyperuricemia","status":"COMPLETED","sponsor":"Sanofi","startDate":"2005-06","conditions":"Nutritional and Metabolic Diseases","enrollment":30},{"nctId":"NCT00230217","phase":"PHASE4","title":"Study of Rasburicase as Treatment or Prevention of Hyperuricemia Associated With Tumor Lysis Syndrome in Patients With Relapsed or Refractory Lymphoma, Leukemia, or Solid Tumor Malignancy","status":"COMPLETED","sponsor":"Sanofi","startDate":"2004-03","conditions":"Tumors, Hyperuricemia, Tumor Lysis Syndrome","enrollment":94},{"nctId":"NCT00651911","phase":"PHASE4","title":"Fasturtec TLS Treatment / Prophylysis","status":"COMPLETED","sponsor":"Sanofi","startDate":"2003-07","conditions":"Tumor Lysis Syndrome","enrollment":45},{"nctId":"NCT00563771","phase":"PHASE4","title":"Rasburicase for Treatment of Hyperuricemia in Children and Adolescence Patients With Tumor Lysis Syndrome","status":"COMPLETED","sponsor":"Sanofi","startDate":"2003-03","conditions":"Hyperuricemia","enrollment":38}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Rasburicase (SR29142)","genericName":"Rasburicase (SR29142)","companyName":"Sanofi","companyId":"sanofi","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Rasburicase is an enzyme used to treat conditions such as Leukemia, Lymphoma, Tumor Lysis Syndrome, Hyperuricemia, and Gout. It works by breaking down uric acid through its action as a uric acid oxidative enzyme.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}